Microbicides: latest news

Microbicides resources

  • Microbicides

    Microbicides are any substances which protect people against infection by microbes, such as viruses or bacteria, on contact with those microbes....

    From: Preventing HIV

    Information level Level 4
  • Microbicides

    A microbicide is a topical agent that, when applied to a mucosal surface, serves as a barrier to infection. Microbicides can come in the form of...

    From: HIV transmission & testing

    Information level Level 4

Microbicides features

Microbicides news from aidsmap

More news

Microbicides news selected from other sources

  • Are antimicrobial condoms the new frontier against STIs? Not quite…

    Australian biotech company Starpharma has announced the imminent launch of a condom coated with an antimicrobial chemical known as VivaGel. While it might be marketed as a great leap forward for preventing sexually transmitted infections (STIs), it’s unlikely to offer any more protection than your average condom.

    14 October 2014 | The Conversation
  • Advocates Applaud Launch of MTN-017, World’s First Phase II Rectal Microbicide Study

    IRMA applauds the launch of the world’s first-ever Phase II rectal microbicide trial. The Microbicide Trial Network’s study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.

    02 October 2014 | IRMA
  • Give Some LOVE to IRMA for Give OUT Day

    Give OUT Day shines a spotlight on organizations that empower LGBTQ communities across the country, and the AIDS Foundation of Chicago (AFC) is among these charities.We’re using this campaign to highlight the next generation of HIV prevention: rectal microbicides. Though they’re still in development, these agents can be added to things like lubricants that will prevent the transmission of HIV, revolutionizing the way we protect ourselves and others.

    25 September 2014 | IRMA
  • HIV-fighting intravaginal ring research nets $20M from NIH

    The U.S. National Institutes of Health devoted $20 million to a group of institutions including Miriam Hospital in Rhode Island to develop an HIV drug-delivering intravaginal ring. The design of a successful ring is a priority in HIV research, and the sustained release of drugs the ring offers could eventually play a crucial role in HIV prevention in the developing world.

    15 September 2014 | Fierce Drug Delivery
  • Semi-soft vaginal drug-delivery suppository could limit spread of HIV, AIDS

    A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences. A semi-soft vaginal suppository made from the seaweed-derived food ingredient carrageenan and loaded with the antiviral drug Tenofovir provides a woman-initiated, drug-delivery vehicle that can protect against the spread of sexually transmitted infections during unprotected heterosexual intercourse, the researchers said.

    02 September 2014 | Medical News Today
  • Weaving HIV protection: UW researchers use fabric to protect women against infection

    Scientists use a method of weaving the drug into silk-like fibers that dissolve quickly when inserted into the vagina before sex, delivering a higher dose than is possible with other topical methods currently being tested.

    05 August 2014 | Business Journal
  • ASPIRE Phase III trial of a vaginal ring for HIV prevention completes enrollment of 2,629 women

    MTN’s trial testing dapivirine ring on track to finish next year; IPM’s sister Phase III trial ongoing.

    30 June 2014 | Microbicide Trials Network
  • Rectal tenofovir gel yields much higher rectal and vaginal levels than oral tenofovir

    Tenofovir 1% gel applied rectally yielded rectal tissue concentrations orders of magnitude greater than those achieved with oral tenofovir, according to results of an 18-person study by US researchers. Systemic tenofovir exposure was lower with 1% gel than with oral tenofovir, but vaginal exposure was greater with the rectal gel.

    02 June 2014 | NATAP
  • IPM Receives Worldwide Rights to HIV Prevention Medicines

    The International Partnership for Microbicides (IPM) announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

    09 May 2014 | International Partnership for Microbicides
  • Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum

    Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections in both the vagina and rectum in animals: HIV, herpes simplex virus 2, and human papillomavirus.

    22 April 2014 | Eurekalert Medicine & Health
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.